MRC Centre for Neuromuscular Diseases, University College London, Box 102, 8-11 Queen Square, WC1N 3BG London, UK.
Division of Rheumatology, Allergy, Clinical Immunology, School of Medicine, UC Davis, 1911 Geneva Place, Davis, CA, USA.
Best Pract Res Clin Rheumatol. 2014 Oct;28(5):711-28. doi: 10.1016/j.berh.2014.10.004. Epub 2014 Nov 7.
In addition to the critical need of measuring tools for drug development of spondyloarthritis (SpA), these tools are also valuable for patient management. An early diagnosis, determination of early therapeutic response, and monitoring therapeutic response have now become increasingly important because effective therapies are available, and therapies such as anti-tumor necrosis factor (TNF) drugs are even more effective if used in early disease stages. In this review, we focus on disease activity measurements and monitoring in axial SpA and psoriatic arthritis (PsA). Both axial SpA and PsA have heterogeneous clinical manifestations. Therefore, in addition to the measurement of each clinical domain, composite measures inclusive of all clinical domains can be very helpful and are more likely to give complete and reliable information about the disease activity. A major focus of this review is to describe the recently developed composite measures for axial SpA and PsA.
除了对脊柱关节炎（SpA）药物开发的测量工具的迫切需求外，这些工具对于患者管理也具有重要价值。早期诊断、早期治疗反应的确定以及治疗反应的监测现在变得越来越重要，因为有效的治疗方法已经可用，如果在疾病早期阶段使用抗肿瘤坏死因子（TNF）药物等治疗方法，效果会更好。在这篇综述中，我们重点介绍了轴性 SpA 和银屑病关节炎（PsA）的疾病活动度测量和监测。轴性 SpA 和 PsA 均具有异质性的临床表现。因此，除了对各个临床领域的测量外，包括所有临床领域的综合测量也非常有帮助，并且更有可能提供关于疾病活动度的完整和可靠的信息。这篇综述的一个主要重点是描述最近为轴性 SpA 和 PsA 开发的综合测量方法。
